Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:13:07.835Z.
Calculation as of: 2026-10-06T21:13:07.835Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fae3dac89f6aae568c3e1e6131ec6a0b9ed594063ed7dd46d2bf25dadf8b5230
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
OKYO Pharma Limited
Market Cap
$56.02M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| OKYO Pharma Limited (OKYO) | $56.02M | N/A |
| Aldeyra The (ALDX)vs › | $55.25M | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | N/A |
| Talphera, Inc. (TLPH)vs › | $57.61M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $54.14M | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.70M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $58.43M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
